This Article Abstract Full Text Full Text (PDF) View PREMIER Trial Participants Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hudson, M. P. Articles by Weaver, W. D. Search for Related Content PubMed PubMed Citation Articles by Hudson, M. P. Articles by Weaver, W. D. Related Collections Related Article

Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction

Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) Trial

Michael P. Hudson, MD, FACC^_*, Paul W. Armstrong, MD, FACC^,c, Witold Ruzyllo, MD^,d, Jose Brum, MD^,a, Lisa Cusmano, MS^,a, Piotr Krzeski, MD^,a, Robert Lyon, PhD^,a, Miguel Quinones, MD, FACC^||,d, Pierre Theroux, MD, FACC^¶,b,d, Diana Sydlowski, MS^_*, Henry E. Kim, MD, FACC^_*, Mario J. Garcia, MD, FACC^#, Wael A. Jaber, MD, FACC^# and W. Douglas Weaver, MD, FACC^_*,d,_*

^_* Henry Ford Heart and Vascular Institute, Detroit, Michigan
University of Alberta, Edmonton, Alberta, Canada
National Institute of Cardiology, Warsaw, Poland
Procter & Gamble Pharmaceuticals, Cincinnati, Ohio
^|| Montreal Heart Institute, Montreal, Quebec, Canada
^¶ Baylor College of Medicine, Houston, Texas
^# Cleveland Clinic Foundation, Cleveland, Ohio.

View larger version (18K): [in a new window]   Figure 1 Primary end point/change in left ventricular diastolic volume index (LVEDVI), baseline to 90 days.